A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries : Clinical Journal of the American Society of Nephrology

Journal Logo

Editorial

A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States

The Cost-Effectiveness of Dapagliflozin in Three European Countries

Khine, Annika1; Lin, Eugene2,3,4

Author Information
CJASN 17(12):p 1707-1709, December 2022. | DOI: 10.2215/CJN.09900822
Copyright © 2022 by the American Society of Nephrology

Full Text Access for Subscribers:

You can read the full text of this article if you:

Access through Ovid